Eli Lilly shares rise 1.89% on retatrutide TRANSCEND-T2D-2 Phase 3 diabetes trial win ahead of earnings

Eli Lilly announced positive topline results from its Phase 3 TRANSCEND-T2D-2 trial of retatrutide, an investigational once-weekly triple agonist targeting GIP, GLP-1 and glucagon receptors. The open-label trial enrolled 1,298 adults with type 2 diabetes. Shares gained 1.89% to $1,312.68 in after-hours trading.

Detected & updated continuously · Source: Nebula